<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342367</url>
  </required_header>
  <id_info>
    <org_study_id>10-625-A</org_study_id>
    <nct_id>NCT01342367</nct_id>
  </id_info>
  <brief_title>Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer</brief_title>
  <official_title>A Feasibility Study of Oral Hormonal Therapy and Radiation for Non-metastatic, Intermediate or High Risk Prostate Cancer in Men 70 and Older or With Medical Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is see if quality of life is improved in patients receiving oral
      hormone therapy compared to standard of care. The study will also compare survival rates
      between patients receiving oral hormone therapy and those receiving standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2010</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Health-related quality of life will be summarized using a score reflecting patient reported symptoms in sexual, hormone/vitality, fatigue, and overall quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Increase in prostate specific antigen (PSA)measured over time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Androgen Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two oral hormonal drugs (bicalutamide with dutasteride or bicalutamide with finasteride)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.</description>
    <arm_group_label>Oral Androgen Therapy</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.</description>
    <arm_group_label>Oral Androgen Therapy</arm_group_label>
    <other_name>Avodart</other_name>
    <other_name>Jalyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride</intervention_name>
    <description>Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.</description>
    <arm_group_label>Oral Androgen Therapy</arm_group_label>
    <other_name>Propecia</other_name>
    <other_name>Proscar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.</description>
    <arm_group_label>Oral Androgen Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 70 years and/or Charlson comorbidity index score &gt; or = 2

          -  Pathologically (histologically) proven diagnosis of prostatic adenocarcinoma

          -  Two or more of the following intermediate risk features for recurrence, Gleason Score
             = 7, PSA 10-20 ng/ml, Clinical Stage T2b-T2c Percent positive biopsy cores &gt; or = 50%

          -  One or more of the following high risk features for recurrence, Gleason Score 8-10,
             PSA &gt; 20 ng/ml, Clinical Stage T3a-T4

          -  Clinically negative lymph nodes as established by imaging, nodal sampling, or
             dissection

          -  No evidence of bone metastases on bone scan

          -  History/physical examination via the Charlson Comorbidity Index within 60 days prior
             to registration

          -  Zubrod Performance Status 0-2

          -  Age &gt; or = 18

          -  Baseline serum PSA within 60 days prior to registration

          -  Baseline serum testosterone obtained within 60 days prior to registration

          -  Study entry PSA and serum testosterone must not be obtained during the following time
             frames, 10-day period following prostate biopsy, following initiation of oral androgen
             manipulation, within 30 days after discontinuation of finasteride or dutasteride

          -  CBC/ differential obtained within 60 days prior to registration with adequate bone
             marrow function

          -  Patient must be able to provide study-specific informed consent prior to study entry

          -  Liver function parameters as follows, Total Bilirubin &lt; or = 2 x institutional upper
             limit of normal, AST (SGOT) or ALT (SGPT) &lt; or = 2 x institutional upper limit normal

        Exclusion Criteria:

          -  Prior radical surgery (prostatectomy), high-intensity focused ultrasound (HIFU) or
             cryosurgery for prostate cancer

          -  Prior hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide),
             antiandrogens (e.g., flutamide, bicalutamide), estrogens (e.g., DES), or bilateral
             orchiectomy

          -  Use of 5-alpha reductase inhibitors (finasteride, dutasteride) specifically prescribed
             for the treatment of prostate cancer

          -  Prior or concurrent cytotoxic chemotherapy for prostate cancer; prior chemotherapy for
             a different cancer is permitted

          -  Prior radiation, including brachytherapy, to the region of the prostate that would
             result in overlap of RT fields

          -  Active lupus or scleroderma

          -  Severe, active co-morbidity, including but not limited to,unstable angina within the
             last 6 months without subsequent corrective cardiovascular procedure,or acute
             bacterial or fungal infection requiring intravenous antibiotics at the time of
             registration

          -  Hepatic insufficiency with AST, ALT, or Bilirubin &gt; 2 x upper limit of normal,clinical
             jaundice, and/or coagulation defects

          -  Acquired Immune Deficiency Syndrome (AIDS); note, however, that HIV testing is not
             required for entry into this protocol.Patients who are HIV seropositive but do not
             meet criteria for diagnosis of AIDS are eligible for study participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Liauw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fauzia Arif</last_name>
      <email>farif@radonc.uchicago.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Finasteride</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

